Issue 29, 2010

Discovery of potent inhibitor for farnesyl pyrophosphate synthase in the mevalonate pathway

Abstract

The mevalonate pathway is an important drug target for the treatment of cancer and cardiovascular disease. We synthesized and studied a new type of nitrogen-containing bisphosphonate analogs and developed a sensitive end point assay method for enzyme FPPS, which was used for inhibitor screening. One potent FPPS inhibitor was discovered, and the structure–activity relationship of bisphosphonates for the enzyme inactivation was studied.

Graphical abstract: Discovery of potent inhibitor for farnesyl pyrophosphate synthase in the mevalonate pathway

Supplementary files

Article information

Article type
Communication
Submitted
17 Apr 2010
Accepted
20 May 2010
First published
14 Jun 2010

Chem. Commun., 2010,46, 5340-5342

Discovery of potent inhibitor for farnesyl pyrophosphate synthase in the mevalonate pathway

J. Gao, X. Chu, Y. Qiu, L. Wu, Y. Qiao, J. Wu and D. Li, Chem. Commun., 2010, 46, 5340 DOI: 10.1039/C0CC00992J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements